Can Monsanto Company Continue to Deliver Growth to Your Portfolio?

Biotech seed producer and agricultural sciences firm Monsanto Company (NYSE: MON  ) has returned outsized gains to investors over its life as a public company. In fact, the company's stock has returned 640% in the last decade -- walloping the S&P 500 by more than 580% in that time. What has driven shares higher? While we can point to swelling top and bottom lines as the primary reason, we shouldn't forget that pipeline success ultimately determines growth. Can a company as mature as Monsanto continue to innovate and deliver growth in the years ahead?

Growth opportunities abound
First, let's note that investors shouldn't expect another 640% gain (not anytime soon, anyway) from a company sporting a market cap of $57 billion. That doesn't mean Monsanto is done growing, however. Consider that a record 29 of more than 70 pipeline projects advanced in development the last year. The progress included more than 10 products from the company's new technology platform and five products that were successfully commercialized. Here's how the highlights break down by platform:

Technology Platform

Pipeline Advancements

Highlighted Products

Biotechnology

9

Intacta RR2 PRO soybeans, next-gen SmartStax PRO corn

Breeding

7

Enhanced resistance to Gray Lead Spot (corn), Resistance to Bacterial Wilt (tomatoes), Downy Mildew (lettuce)

Biologicals

5

BioDirect Bee Health

Integrated Farming Systems

8

Weather-enhanced soybeans and corn

Source: Monsanto.

While the progress and future growth opportunities are astounding, I'll bet many readers aren't aware that Monsanto has multiple platforms. For instance, the company's breeding platform uses traditional, non-genetically modifying (well, even breeding is genetically modifying) techniques to introduce disease resistance to various crop varieties. In fact, Monsanto's breeding platform is the most advanced in the industry. Remember that the next time you tout "natural" agricultural methods.

Meanwhile, the biologicals platform works to create products that improve crop health and productivity. Monsanto is just beginning to research the technology, but it hasn't been shy about investing in it. In 2011, it made a highly criticized acquisition of bee health biotech company Beeologics, which has become an integral part of the platform today. Ironically, the company most (mistakenly) associated with colony collapse disorder, or CCD, in honey bees could become their savior. (Product candidates under development for supporting bee health are using RNAi to target two viruses that commonly target honey bees, which are the scientifically proven culprits of CCD.)

More recently, Monsanto partnered with leading industrial enzymes and microbial products company Novozymes to bolster future development of agricultural biologicals. It also made a generous $300 million upfront payment to solidify the game-changing alliance and acknowledge Novozyme's leading technology. How big is the platform's potential? The global opportunity for microbial solutions in agricultural applications stood at $2.3 billion and has grown at a mid-teen annual clip, although its a nascent field that is just beginning to grow in importance. Early adopters such as Monsanto and Novozymes stand to reap the greatest rewards.

Foolish bottom line
Monsanto has largely relied on its industry-leading biotechnology platform in the last decade. While the platform will continue to make substantial contributions going forward, the company is making significant progress with multiple complementary platforms that have amazing growth potential. Investors cannot expect every product candidate to be successfully commercialized, but there's no reason to believe long-term growth is anywhere near finished. Monsanto expects mid-to-high teens operational growth and, quite frankly, I can't disagree.

Can't invest in Monsanto? 
A company as controversial as Monsanto isn't fit for every investor, but there are other growth opportunities. And, let's face it, there's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (5) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 29, 2014, at 8:28 AM, funfundvierzig wrote:

    The shrewdly executed combination of Monsanto, the leading seed innovator with Novozmes, the leading enzyme and food additives enterprise is unbeatable. The venture is no match for Danisco, which was gobbled up by DuPont for $7 billion and has been carved up and subsumed into the uninspiring conglomerate bureaucracy of the lagging DuPont Company…funfun..

  • Report this Comment On January 29, 2014, at 12:02 PM, getthefacts4 wrote:

    there are lost of comments about Monsanto's struggle with opposition to GM crops but it has grown multi fold. If we finally had the EU and China cultivating GM crops (like the rest of the world) you could see another 6 -10x increase just from existing products being grown more.Add to this new products in the next 10 years and it would be easy to get to a market cap of $500B.

  • Report this Comment On January 29, 2014, at 12:02 PM, getthefacts4 wrote:

    there is also a lot of comments........

  • Report this Comment On January 29, 2014, at 2:20 PM, TMFBlacknGold wrote:

    @getthefacts4

    If only there was an edit button available for recent comments...I like that you're a good sport about it, though.

    There is some good news: China and the EU (Spain and several others) are beginning to plant larger quantities of biotech seeds. I'm not sure what market share Monsanto holds, but I do know China has invested vast amounts in local biotech seed producers. It will be interesting to see how it all plays out.

    Maxxwell

  • Report this Comment On January 29, 2014, at 5:56 PM, dockofthebay wrote:

    Your comments about 2 viruses having been "scientifically proven culprits of CCD" is way off base if you are implying that these viruses are the sole causes of CCD. The causes of CCD are still under study and there are apparently many factors at work in CCD. The added effect of exposure to neonicotinoids seems to be an important component. The fact that "neonics" are systemically drawn into every part of the plant and remain there makes a bad situation for pollinators even worse.

Add your comment.

DocumentId: 2811228, ~/Articles/ArticleHandler.aspx, 4/16/2014 12:18:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.


Advertisement